Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 8/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.32 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.31 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.31 |
| ▸ | HTR1F | P30939 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16621981 | 0.84 | RXFP1 (0.42) | RXFP1MAPTFFAR2ACKR3HTR1F | |
| SCHEMBL9939495 | 0.83 | RXFP1 (0.41) | RXFP1MAPTKIF18AFFAR2HTR1F | |
| SCHEMBL9939756 | 0.82 | RXFP1 (0.37) | RXFP1KIF18AFFAR2HTR1F | |
| SCHEMBL16621982 | 0.81 | RXFP1 (0.40) | RXFP1MAPTKIF18AFFAR2HTR1F | |
| SCHEMBL9939541 | 0.79 | CYP2D6 (0.38) | RXFP1CTPS1KIF18AFFAR2BRAF | |
| SCHEMBL9938519 | 0.78 | VNN1 (0.37) | RXFP1 | |
| SCHEMBL9939758 | 0.74 | MEN1 (0.37) | IDO1MAPT | |
| SCHEMBL9939769 | 0.74 | HSD11B1 (0.38) | KIF18AACKR3 | |
| SCHEMBL9921073 | 0.73 | CCNA2 (0.42) | IDO1MAPT | |
| SCHEMBL9939766 | 0.73 | BRAF (0.35) | RXFP1MAPTKIF18ABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9370507-B2 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150335625-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335625-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1B | IDO1 2254/4885RXFP1 3462/4885MAPT 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.